Abstract: The present Disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or a derivative thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.
Type:
Application
Filed:
November 10, 2023
Publication date:
March 14, 2024
Applicants:
MESHABERASE, LLC, The United States of America, as Represented by the Secretary, Department of Health & Human Services
Inventors:
Benjamin Rubin, Mark Gilbert, Jinkyu Jung
Abstract: The present Disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or a derivative thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.
Type:
Grant
Filed:
June 2, 2021
Date of Patent:
December 19, 2023
Assignees:
MESHABERASE, LLC, The United States of America, as Represented by the Secretary, Department of Health and Human Services
Inventors:
Benjamin Rubin, Mark Gilbert, Jinkyu Jung
Abstract: The present Disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or a derivative thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.
Type:
Application
Filed:
June 2, 2021
Publication date:
September 23, 2021
Applicants:
MESHABERASE, LLC, United States Department of Health and Human Services, National Institutes of Health
Inventors:
Benjamin Rubin, Mark Gilbert, Jinkyu Jung
Abstract: The present Disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or a derivative thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.
Type:
Grant
Filed:
October 7, 2019
Date of Patent:
July 6, 2021
Assignees:
MESHABERASE, LLC, The United States of America, as Represented by the Secretary, Dept of Health and Human Services
Abstract: Methods for treating or inhibiting dysfunctional tear syndrome (DTS) or symptoms associated therewith, and compositions for use in the methods.
Abstract: The present Disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or a derivative thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.
Type:
Application
Filed:
October 7, 2019
Publication date:
May 14, 2020
Applicants:
MESHABERASE, LLC, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
Abstract: The present Disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or a derivative thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.
Type:
Application
Filed:
January 10, 2019
Publication date:
May 16, 2019
Applicants:
MESHABERASE, LLC, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
Abstract: The present disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or derivatives thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.